Marketing-authorisation holder · Denmark
Ascendis Pharma Bone Diseases A/S
5 medicines in 3 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Denmark
5 medicines in 3 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
5 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| YORVIPATHSoluzione iniettabile | Palopegteriparatide | Italy | Authorised | |
| Yorvipath | Palopegteriparatide | EU (EMA) | Authorised | 2023 |
| YORVIPATH 168 MICROGRAMOS/0,56 ML SOLUCION INYECTABLE EN PLUMA PRECARGADA1935 µg · Solución inyectable en pluma precargada | Palopegteriparatide | Spain | Marketed | 2024 |
| YORVIPATH 294 MICROGRAMOS/0,98 ML SOLUCION INYECTABLE EN PLUMA PRECARGADA3387 µg · Solución inyectable en pluma precargada | Palopegteriparatide | Spain | Marketed | 2024 |
| YORVIPATH 420 MICROGRAMOS/1,4 ML SOLUCION INYECTABLE EN PLUMA PRECARGADA4838 µg · Solución inyectable en pluma precargada | Palopegteriparatide | Spain | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 3 | 3 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
| Italy | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.